000101238 001__ 101238
000101238 005__ 20181203020748.0
000101238 022__ $$a0969-7128
000101238 037__ $$aARTICLE
000101238 245__ $$aContinuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts
000101238 260__ $$c1998
000101238 269__ $$a1998
000101238 336__ $$aJournal Articles
000101238 500__ $$aDivision of Surgical Research, Centre Hospitalier Universitaire Vaudois, Lausanne University Medical School, Switzerland.
000101238 520__ $$aThe transplantation of polymer encapsulated myoblasts genetically engineered to secrete erythropoietin (Epo) may obviate the need for repeated parenteral administration of recombinant Epo as a treatment for chronic renal failure, cancer or AIDS-associated anemia. To explore this possibility, the human and mouse Epo cDNAs under the control of the housekeeping mouse PGK-1 promoter were transfected into mouse C2C12 myoblasts, which can be terminally differentiated upon exposure to low serum-containing media. Pools releasing 150 IU human Epo per 10(6) cells per day and 390 IU mouse Epo per 10(6) cells per day were selected. Polyether-sulfone (PES) capsules loaded with approximately 200,000 transfected myoblasts from these pools were implanted on the dorsal flank of DBA/2J, C3H and C57BL/6 mice. With human Epo secreting capsules, only a transient increase in the hematocrit occurred in DBA/2J mice, whereas no significant response was detected in C3H or C57BL/6 mice. On the contrary, all mice implanted with capsules releasing mouse Epo increased their hematocrit over 85% as early as 7 days after implantation and sustained these levels for at least 80 days. All retrieved implants released Epo and contained well preserved myoblasts. Moreover most capsules were surrounded by a neovascularization. Mice transplanted with nonencapsulated C2C12 cells releasing mouse Epo showed only a transitory elevation of their hematocrit reflecting the poor engraftment of injected myoblasts. These results indicate that polymer encapsulation of genetically engineered myoblasts is a promising approach for the long-term delivery of bioactive molecules, allowing the resolution of the shortcomings of free myoblast transfer.
000101238 6531_ $$aAcquired Immunodeficiency Syndrome/complications
000101238 6531_ $$aAnalysis of Variance
000101238 6531_ $$aAnemia/etiology/ therapy
000101238 6531_ $$aAnimals
000101238 6531_ $$aAntibodies
000101238 6531_ $$aMonoclonal/blood
000101238 6531_ $$aCapsules
000101238 6531_ $$aCell Line
000101238 6531_ $$aErythropoietin/ administration & dosage/genetics/ secretion
000101238 6531_ $$aFemale
000101238 6531_ $$aGene Therapy/ methods
000101238 6531_ $$aGenetic Engineering/methods
000101238 6531_ $$aGenetic Vectors
000101238 6531_ $$aHematocrit
000101238 6531_ $$aHumans
000101238 6531_ $$aInjections
000101238 6531_ $$aIntramuscular
000101238 6531_ $$aKidney Failure
000101238 6531_ $$aChronic/complications
000101238 6531_ $$aMice
000101238 6531_ $$aMice
000101238 6531_ $$aInbred C3H
000101238 6531_ $$aMice
000101238 6531_ $$aInbred C57BL
000101238 6531_ $$aMice
000101238 6531_ $$aInbred DBA
000101238 6531_ $$aMuscle
000101238 6531_ $$aSkeletal/cytology/ secretion/ transplantation
000101238 6531_ $$aNeoplasms/complications
000101238 6531_ $$aTime Factors
000101238 6531_ $$aTransfection
000101238 700__ $$0240795$$aRegulier, E.$$g150344
000101238 700__ $$aSchneider, B. L.
000101238 700__ $$0241685$$aDeglon, N.$$g150324
000101238 700__ $$aBeuzard, Y.
000101238 700__ $$0240206$$aAebischer, P.$$g104359
000101238 773__ $$j5$$k8$$q1014-22$$tGene Ther
000101238 909C0 $$0252067$$pLEN$$xU10457
000101238 909CO $$ooai:infoscience.tind.io:101238$$pSV$$particle
000101238 937__ $$aLEN-ARTICLE-1998-005
000101238 970__ $$a77/LEN
000101238 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000101238 980__ $$aARTICLE